Did Leronlimab reduce the number of mild/moderates progressing to severe/critical in CD10?

This might be a reason to run a Phase III Moderate trial (no milds) with a increase in the number of patients to see if the number of people progressing to severe/critical is reduced. The small number of milds and moderates in the phase II were probably not enough to prove this, if I understand the results correctly.

But if this is the case, the results from CD12 would likely come into play sooner than a moderate phase III.